Drug intelligence / Profile preview

OPGx-MERTK

Development stage: Preclinical
Lead developer: Opus Genetics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Subretinal

Overview

OPGx-MERTK is an investigational adeno-associated virus (AAV)-based gene therapy developed by Opus Genetics for the treatment of retinitis pigmentosa caused by mutations in the MERTK gene. The therapy aims to deliver a functional copy of the MERTK gene to retinal cells via subretinal injection, with the goal of restoring or preserving visual function in patients affected by this inherited retinal disease. Preclinical studies have demonstrated efficacy in animal models, and as of early 2025, OPGx-MERTK remains in preclinical development[1][2][3][4][6].

Targets

MERTK (MER proto-oncogene, tyrosine kinase)

Beyond the preview

Go deeper on OPGx-MERTK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPGx-MERTK.

Explore the full profile